Confronto
Octreotide vs. Selank
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
83150-76-9
129954-34-3
Peso molecolare
1019.24 g/mol
751.85 g/mol
Emivita
1.7 h
0.3 h
Sequenza
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Thr-Lys-Pro-Arg-Pro-Gly-ProMeccanismo d'azione
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
5
4
di cui sull'uomo
4
2
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Octreotide and Selank?
- Octreotide is classified as "Ricerca (altro)", while Selank is classified as "Ricerca (altro)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Octreotide or Selank?
- The highest available evidence level is "RCT sull'uomo" for Octreotide and "Studio sull'uomo" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Octreotide and Selank in Germany and the United States?
- Germania: Octreotide — Su prescrizione, Selank — Non approvato. Stati Uniti: Octreotide — Su prescrizione, Selank — Non approvato. These are factual summaries with source and review date on the individual pages.